Live Breaking News & Updates on Esmo 2023

Stay updated with breaking news from Esmo 2023. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ESMO 2023 Updates in Endometrial and Cervical Cancer Give Glimpse Into Future Care

Updated data from several clinical trials in both endometrial and cervical cancer could signal the emergence of multiple effective treatment options coming down the pike. ....

Sri Lanka , United States , Davidm Omalley , Gonzalez Martin , Gallardo Rinc , Onclive Peer Exchange , European Society For Medical Oncology , Hispanic Black , European Society , Medical Oncology , Advanced Recurrent Endometrial , Recurrent Metastatic Cervical , Prescription Drug User Fee , Transduct Target , Esmo 2023 ,

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer. ....

Bladder Cancer , Non Muscle Invasive Bladder Cancer , Esmo 2023 , Highlights From Esmo 2023 , Molecular Biomarkers ,

Diagnosing and Staging Patients With Endometrial Cancer

Expert gynecologic oncologists discuss recent progress in treating advanced endometrial and cervical cancers, including epidemiology, risk factors, evaluation, staging, and molecular testing. ....

Recent Advances , Treating Endometrial , Cervical Cancers , Staging Patients With Endometrial , Gynecologic Cancers , Esmo 2023 , Endometrial Cancer , Endometrial Carcinoma , Cervical Cancer , Uterine Cancer , Endometrial Cancer Treatments , Endometrial Cancer Treatment Updates , Cervical Cancer Treatments , Cervical Cancer Treatment Updates ,

Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431

Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023. ....

Benjamin Levy , Randomized Phase , First Line Selpercatinib , Partnership With , Non Small Cell Lung Cancer , Lung Cancer , Libretto 431 , Chemo Io , Safety Data , Efficacy Data , Adverse Events , Toxicity Profile , Pfs Data , Overall Survival Data , Esmo 2023 , Esmo Congress ,

Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial

Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023. ....

Aditya Bardia , Datopotamab Deruxtecan , Primary Results , Randomized Phase , Previously Treated Inoperable , Metastatic Hormone Receptor Positive , Breast Cancer , Metastatic Breast Cancer , Hr Positive , Her2 Negative , Tropion Breast01 , Dato Dxd , Efficacy Data , Safety Data , Adverse Events , Toxicity Profile , Esmo 2023 , Esmo Congress ,